Clinical Trial ResultsNew post-hoc analyses from the Phase 2 VISIONARY-MS OLE study demonstrated improved vision, cognition, and global neurological function following treatment for up to three years.
Financial PositionClene ended the year with $12.2 million in cash, which management believes provides runway to fund ongoing operations through 2Q25.
Regulatory ProgressClene's lead asset, CNM-Au8, has Orphan Drug Designation, which should qualify for Priority Review, potentially speeding up the approval process.